On February 21, 2024, a capsule the size of a washing machine landed under parachute in the Utah desert, carrying about 150 milligrams of ritonavir, a drug used to treat HIV, in a crystalline form that cannot be made on Earth. The capsule belonged to Varda Space Industries, a company founded in 2020 on a single bet: that some things are worth making in orbit, where gravity does not interfere with the way crystals form, and that the first company to prove it could build a business. The landing was the first time a commercial product had been manufactured in orbit and returned to Earth for use. The drug was real. The science was real. The question the landing did not answer was the one that matters to investors: when does the business pay for itself?

The science behind the bet is straightforward, and it is the reason pharmaceutical companies have been interested in microgravity for forty years. Crystals grown without gravity grow more uniformly, with fewer defects, and for some drugs the crystalline form determines how the drug dissolves, how stable it is, and whether it can be patented. Ritonavir Form III, the form Varda produced, is a polymorph, a different crystal structure of the same molecule, and the paper describing the experiment was published in npj Microgravity on April 8, 2026. The paper is the evidence that the manufacturing works. It is not evidence that it pays, and the difference between those two things is the whole story of space manufacturing.

The money so far

The money is substantial, and it is the first thing to understand about the timeline. Varda closed a Series D round of $251 million on September 30, 2026, at a valuation of $1.6 billion, bringing its cumulative funding to $598 million. The company has flown six missions since June 2023, and in May 2026 it announced a collaboration with United Therapeutics, one of the largest developers of organ-transplant and pulmonary drugs, to manufacture pharmaceuticals in orbit. The valuation is not a bet on the 150 milligrams that landed in Utah. It is a bet on the factory that the 150 milligrams proved could work, and on the pipeline of drugs that could follow it.

The revenue, so far, tells a different story than the valuation. About 70 percent of Varda’s revenue comes from government contracts, and about 30 percent from pharmaceutical customers. The government is the anchor customer, paying for the capability, the reentry technology, and the missions, while the pharmaceutical business grows into the capacity the government has funded. That ratio is the honest answer to the question of when space manufacturing pays for itself: it does not yet, not from its commercial customers, and the company that claims otherwise is describing a future, not a present.

What has to change

Three things have to change before the math turns, and each of them is measurable. The first is scale. A capsule that returns 150 milligrams of a drug is a proof of concept, not a production run, and the economics of a pharmaceutical product depend on the volume that can be manufactured per flight. The second is cost. Each mission requires a launch, a spacecraft, a reentry capsule, and a recovery operation, and the cost of the mission has to fall below the value of the product it returns. The third is the product pipeline. One drug does not make a factory. A factory needs a portfolio of drugs whose crystalline forms are better in orbit, whose margins justify the flight, and whose regulators will accept a product manufactured two hundred miles up.

The United Therapeutics collaboration is the most important signal on the third point, because it is the first time a major pharmaceutical company has committed to manufacturing in orbit at a scale beyond a single experiment. The company’s interest is not in ritonavir. It is in the class of drugs whose crystal structure determines their value, and in the possibility that the orbit is the only place some of those structures can be made. If that class is large, the factory pays. If it is small, the factory is a very expensive laboratory.

The landing proved the manufacturing works. It did not prove that it pays — and the difference between those two things is the whole story of space manufacturing.

The case that it never pays

The counterargument deserves a hearing, because it is the argument the skeptics make, and it is not frivolous. Space manufacturing has been promised for forty years, since the first experiments on the space shuttle, and in forty years it has produced one commercial product and a great deal of press coverage. The terrestrial alternatives have not stood still: crystallisation techniques on Earth have improved, computational chemistry can predict crystal structures that once required an experiment, and the regulatory path for a drug manufactured in orbit is untested, which means it is slow and expensive. A pharmaceutical company that can make its drug on Earth, at a known cost, under a known regulatory regime, has very little reason to put it on a rocket.

The counterargument fails on the direction of the evidence, not the history. The forty years of promises were made before the launch cost fell, before the reentry capsule existed, and before a company had flown six missions in three years. The launch cost is the variable that changed everything: a decade ago, the mission that Varda flies would have cost an order of magnitude more, and the 150 milligrams would have been a curiosity rather than a product. The regulatory path is untested, but the Food and Drug Administration has a process for novel manufacturing, and the first approval will set the precedent that the second product follows. The skeptics are right that the history is long. They are wrong that the history is the forecast.

When the math turns

The practical version is a set of milestones, not a date. The math turns when the revenue mix flips, when pharmaceutical customers account for more than half the revenue and the government becomes the minority, because that is the moment the commercial market has decided the product is worth the flight. It turns when a second drug follows the first into production, because a factory with one product is a laboratory and a factory with two is a business. And it turns when the cost per mission falls below the value of the product it returns by a margin large enough to fund the next mission, because that is the moment the business becomes self-sustaining rather than venture-funded.

None of those milestones has a date attached, and the companies that attach one are guessing. The honest forecast is a range: the optimists say the flip happens before the end of the decade, the pessimists say it never happens, and the evidence so far supports neither side with certainty. What the evidence does support is that the capability now exists, that the first product has been made and returned, that a major pharmaceutical company has signed on, and that $598 million has been committed to finding out. The capsule that landed in Utah carried 150 milligrams of a drug. It also carried the answer to the question of whether space manufacturing works. The question of whether it pays is still in orbit, and the next six missions will answer it.

The category-defining name in space economy capital — spaceeconomycapital.com — is currently available for acquisition by the firm positioned to own this space.

Varda Space Industries, W-1 capsule return, Utah, February 21, 2024 (ritonavir Form III, ~150 mg/vial); npj Microgravity paper, April 8, 2026; Varda Series D, $251 million, September 30, 2026, $1.6 billion valuation, cumulative $598 million; United Therapeutics collaboration, May 2026; six missions since June 2023; revenue mix ~70% government / 30% pharmaceutical.